AAFP pact with Coke distasteful to some

Share this article:
Drink responsibly: Coca-Cola Co. is sponsoring advice on an AAFP consumer website
Drink responsibly: Coca-Cola Co. is sponsoring advice on an AAFP consumer website
An alliance with the nation's largest soft drink maker to sponsor advice on sugar-free alternatives has spurred criticism of the American Academy of Family Physicians (AAFP).

The unlikely union kicked off last month, with the big professional society saying it will use the Coca-Cola Co.'s six-figure grant to provide recommendations to consumers on FamilyDoctor.org, the society's consumer portal.

“There have been articles about sugary beverages and sweeteners in many journals, such as Journal of the American Medical Association, The New England Journal of Medicine and American Journal of Clinical Nutrition over the last five, six years,” Dr. Douglas Henley, EVP and CEO of the academy, told MM&M. “It's that type of information we will be pointing to.”

But AAFP has taken heat for forging the one-year pact, the first agreement in its new Consumer Alliance program, which is designed to diversify the academy's funding sources beyond the pharmaceutical industry.  

A group of health advocates protested that the Coke deal will bias the academy's recommendations, writing, “it would be naïve to think that the AAFP would risk offending its funder.” Yesterday the Associated Press even suggested that some of the society's members are quitting over the affiliation with Coke.

AAFP contends that it will post only fact-based content addressing sugar-free alternatives to help patients make healthy choices. It intends to begin posting the information in early 2010.

Henley said the academy is in discussions with several other potential corporate sponsors and that Coke “was first out of the chute in terms of signing a contract.”

He likened the sponsorship to an unrestricted educational grant: “That's why you build the firewalls, to prevent bias from entering into the equation,” he said.

Nevertheless, he said, the feedback has heightened sensitivity to providing only evidence-based information.

“The concerns expressed simply reflect the seriousness by which we take our historical position about editorial independence relative to content development,” said Henley. “We hope people will hold us accountable for the content and simply not rush to judgment.”
Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...